Akari Therapeutics Plc
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations
and Comprehensive Loss
(amounts in thousands, except share and per share data)
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $249 | $143 | $1,729 | $5,736 |
| General and administrative | 1,975 | 1,709 | 7,139 | 6,616 |
| Impairment loss on other intangible assets | 5,180 | — | 5,180 | — |
| Merger-related costs | — | 992 | — | 2,290 |
| Restructuring and other costs | — | 83 | — | 1,723 |
| Loss from operations | (7,404) | (2,927) | (14,048) | (16,365) |
| Other income (expense): | ||||
| Interest income | 1 | 3 | 1 | 7 |
| Interest expense | (121) | (69) | (226) | (120) |
| Gain on settlement of current liabilities | 774 | — | 2,018 | — |
| Loss on debt extinguishment | (967) | — | (967) | — |
| Change in fair value of warrant liabilities | 253 | 30 | 333 | 528 |
| Foreign currency exchange gain (loss), net | 76 | 68 | (99) | (67) |
| Loss on derivative liability | (100) | — | (100) | — |
| Other expense, net | — | — | — | (2) |
| Total other income (expense), net | (84) | 32 | 960 | 346 |
| Net loss before income taxes | (7,488) | (2,895) | (13,088) | (16,019) |
| Benefit from deferred income taxes | 1,088 | — | 1,088 | — |
| Net loss | $(6,400) | $(2,895) | $(12,000) | $(16,019) |
| Net loss per share –– basic and diluted | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
| Weighted-average number of Ordinary Shares used in computing net loss per share –– basic and diluted | 65,326,236,698 | 24,386,005,523 | 60,968,766,829 | 18,911,928,794 |
| Comprehensive loss: | ||||
| Net loss | $(6,400) | $(2,895) | $(12,000) | $(16,019) |
| Other comprehensive (loss) income, net of tax: | ||||
| Foreign currency translation adjustment | (38) | (177) | (406) | 114 |
| Total other comprehensive (loss) income, net of tax | (38) | (177) | (406) | 114 |
| Total comprehensive loss | $(6,438) | $(3,072) | $(12,406) | $(15,905) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.